Dengue Literature Review

Reading Plan - ANA and Dengue Dynamics

11 min read

Reading Plan — ANA and Dengue Dynamics

A sequential reading order for all 16 ingested papers, designed to build understanding progressively toward the central question: what happens to antinuclear antibodies in dengue infection, and what does it mean?

Each layer establishes prerequisites for the next. Emphasis areas per paper highlight what to pay closest attention to when reading with the ANA-dengue lens.

Layer 1 — Dengue Foundations

Read this first. Everything else assumes this baseline.

1. raw/Guzman2016.pdf

Guzman2016 - Dengue Infection | Nat Rev Dis Primers | Comprehensive review

Emphasis areas:

  • Section on NS1 biology (three forms: ER-resident, membrane-anchored, secreted sNS1) — this protein is the key molecular mimicry actor in later papers
  • ADE as “conditional virulence” — pre-existing partial immunity determines severity; understand why secondary infection matters
  • Pathophysiology section: sNS1 activates TLR4 on macrophages, disrupts endothelial barrier, binds thrombin, prolongs APTT — these are the downstream effects that Lin2006/Lin2011 attribute partly to autoantibodies
  • Host genetics table (Table 2) — note FcγRIIa polymorphism appears here; it will be central in Garcia2009/2010
  • Complement activation differences between primary (alternative pathway) and secondary (classical, immune-complex-driven) infection
  • Diagnostic tiered structure: understand when serology vs. molecular tests apply (context for ANA timing questions later)

Layer 2 — Dengue Autoimmune Mechanisms

The NS1 molecular mimicry story. Read these as a pair — Lin2006 sets the thesis, Lin2011 extends it with specific molecular targets.

2. raw/lin2006.pdf

Lin2006 - Autoimmune Pathogenesis in Dengue Virus Infection | Viral Immunology | Review of NCKU experimental programme

Emphasis areas:

  • Figure 2 (multifactorial pathogenesis model) — position autoimmunity alongside ADE and direct viral effects
  • Anti-NS1 antibodies cross-react with platelets (IgM, complement-mediated lysis) and endothelial cells (apoptosis via NO/p53/caspase-3)
  • The two distinct endothelial pathology pathways: apoptosis AND inflammatory activation (NF-kB → IL-6, IL-8, MCP-1, ICAM-1)
  • Anti-platelet/anti-endothelial levels are higher in DHF/DSS than DF — severity correlation
  • Note that autoimmunity here is acute-phase, not post-infectious — unusual compared to most infection-triggered autoimmunity (e.g., GBS after Campylobacter)

3. raw/wan2012.pdf

Wan2012 - Autoimmunity in Dengue Pathogenesis | J Formos Med Assoc | Capstone NCKU review

Emphasis areas:

  • Figure 1 (integrated pathogenesis model) — autoimmunity as co-equal to ADE, not subordinate
  • Figure 2 (autoantibody-mediated immunopathogenesis) — anti-NS1/E/prM/C → endothelial cells, platelets, coagulatory molecules
  • Intrinsic ADE hypothesis: FcγR-mediated DENV entry suppresses type I IFN AND promotes IL-10/Th2 — this links ADE mechanistically to autoantibody production
  • New mimicry targets: LYRIC protein (NS1 aa 116-119), RGD structural mimicry, capsid (C) protein
  • Autoantibody kinetics: “peaked in acute phase, declined during convalescent stage, lasted for several months” — compare this explicitly with Garcia2009’s 2-year persistence
  • Case reports: dengue→SLE/lupus nephritis; dengue with autoimmune features — individual cases exist even if population risk is undetectable (Shih2023)
  • NS1 vaccine paradox: protective (complement lysis of infected cells) + pathogenic (autoimmune cross-reactivity) — needs epitope engineering
  • Taiwan epidemiology: adult disease (DF peak 50-54y, DHF peak 60-64y), seasonal importation pattern

4. raw/lin2011.pdf

Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis | Exp Biol Med | Extended molecular targets

Emphasis areas:

  • Specific NS1 host-protein targets: PDI, vimentin, ATP synthase beta, HSP60 — these are the antigens that anti-NS1 autoantibodies recognise on host cells
  • C-terminal NS1 region (aa 311-352) — deletion abolishes cross-reactivity; this is the critical epitope
  • The WGNGCG motif in dengue E protein (aa 101-106) homologous to coagulation factors — a second molecular mimicry axis beyond NS1
  • Anti-prM antibody cross-reactivity with HSP60
  • Comparison across flaviviruses: WGNGCG conserved in haemorrhagic flaviviruses (JEV, WNV, YFV) but absent in HCV — structural basis for flavivirus haemorrhagic phenotype
  • Ask yourself while reading: do these specific cross-reactive targets (PDI, vimentin, HSP60) overlap with known ANA target antigens?

Layer 3 — ANA Baselines

You need to know what “normal” looks like before you can interpret dengue ANA findings. Read these as a reference set — they are short and focused.

5. raw/tan1997.pdf

Tan1997 - ANA Range in Healthy Individuals | Arthritis & Rheumatism | Foundational ANA reference

Emphasis areas:

  • The 15-laboratory multicentre design — this is the standard reference for “healthy ANA”
  • Key numbers: ANA positivity at 1:40 (31.7%), 1:80 (13.3%), 1:160 (5.0%), 1:320 (3.3%) in healthy people
  • Note that ANA positivity is common in healthy people — this is the denominator problem for all dengue-ANA studies
  • HEp-2 substrate — this becomes critical when comparing with Garcia2009 (rat liver)

6. raw/satoh2012.pdf

Satoh2012 - ANA Prevalence in United States | Arthritis & Rheumatism | NHANES population survey

Emphasis areas:

  • 13.8% ANA-positive at 1:80 in the US general population (1999-2004)
  • Demographic correlates: female > male; African Americans > Caucasians; age effects
  • This is the comparator for Garcia2009’s 23.1% post-dengue figure

7. raw/li2019.pdf

Li2019 - ANA Epidemiology in Chinese Healthy Population | J Clin Lab Anal | East Asian baseline

Emphasis areas:

  • 14.01% ANA-positive at >1:100 in Chinese health-checkup population
  • AMA-M2 and anti-SSA as the most common specific autoantibodies in healthy individuals
  • Female predominance; age-related increase
  • Relevant as a non-Western comparator — dengue is primarily a tropical disease affecting non-Western populations

8. raw/dinse2022.pdf

Dinse2022 - Increasing ANA Prevalence in United States | Arthritis & Rheumatology | Temporal trend

Emphasis areas:

  • ANA prevalence rising from 11.0% (1988-1991) to 16.1% (2011-2012) in the US
  • The adolescent increase is particularly striking
  • Critical implication: when comparing dengue-ANA studies from different decades, the moving baseline matters — Garcia2009 data from 2008 should be compared against contemporaneous baselines, not older ones
  • Possible environmental drivers (pollutants, infections, microbiome changes)

9. raw/aringer2019.pdf

Aringer2019 - 2019 EULAR/ACR SLE Classification Criteria | Arthritis & Rheumatology | Clinical threshold

Emphasis areas:

  • ANA >= 1:80 is the mandatory entry criterion for SLE classification (sensitivity 96.1%, specificity 74.4%)
  • The weighted scoring system — understand that ANA alone is insufficient for SLE diagnosis; it is a gate, not a diagnosis
  • This frames why dengue-associated ANA elevation is interesting but does NOT mean dengue causes SLE
  • Skim the specific domain criteria to understand what actual autoimmune disease looks like vs. isolated ANA positivity

Layer 4 — Infection-Triggered Autoimmunity Bridge

These two papers connect infection biology to autoantibody production generally. They provide the framework for interpreting dengue-specific findings.

10. raw/berlin2007.pdf

Berlin2007 - Autoantibodies in Nonautoimmune Individuals during Infections | Ann NY Acad Sci | Multi-infection comparison

Emphasis areas:

  • 21.7% ANA positivity during acute viral infections (HAV, HBV, HCV) vs. 3.8% healthy controls — this is the key comparator number for dengue
  • Anti-annexin-V and anti-prothrombin antibodies across infection types — antiphospholipid-type autoimmunity as a generic infection response
  • The cited transience data: ANA drops from 20.5% to 6.4% between acute and convalescent viral hepatitis — most infection-triggered ANA is self-limiting
  • Ask yourself: does Garcia2009’s 23.1% at 2 years post-dengue break this transience pattern? If so, what is different about dengue?

11. raw/Jhonson2022.pdf

Johnson2022 - Infectious Diseases Autoantibodies and Autoimmunity | J Autoimmun | Mechanistic review

Emphasis areas:

  • The three mechanisms: molecular mimicry, bystander activation, epitope spreading — know the distinctions
  • The critical negative finding: bystander polyclonal activation during severe COVID-19 does NOT significantly elevate ANA above ICU controls — this rules out cytokine storm as a sufficient explanation for ANA in dengue
  • Implication: if bystander activation doesn’t explain dengue ANA, then dengue-specific mechanisms (NS1 mimicry from Layer 2, FcγRIIa-driven IC persistence from Layer 5) become the leading candidates
  • Table of infection-autoimmune disease associations — note which infections cause which autoimmune outcomes

Layer 5 — Dengue Host Response and Genetics

The Cuban and Thai cohort studies. These connect host genetics and immune phenotype to dengue outcome — essential context for understanding why some people develop autoimmune features and others don’t.

12. raw/garcia2010.pdf

Garcia2010 - Asymptomatic Dengue FcγRIIa Polymorphism | Am J Trop Med Hyg | Cuban cohort genetics

Emphasis areas:

  • FcγRIIa-RR131 genotype significantly associated with asymptomatic outcome — the “protective” genotype
  • Conversely, FcγRIIa-HH (from Garcia2009) associates with symptomatic disease and autoimmune markers
  • The biological logic: RR binds IgG2 efficiently → better immune complex clearance → less tissue deposition → less inflammation. HH clears IC poorly → accumulation → persistent inflammation → autoimmune markers
  • This is the genetic bridge between dengue infection and autoimmunity — it explains why only some people develop post-dengue autoimmune features

13. raw/garcia2009.pdf

Garcia2009 - Long-term Clinical Symptoms Post-Dengue | Int J Infect Dis | Post-dengue syndrome

Emphasis areas:

  • 23.1% ANA positivity at 2 years post-dengue — the central finding connecting dengue to ANA
  • 76.9% with at least one autoimmune marker abnormality (CRP, IC, or ANA)
  • Elevated IC correlates with higher anti-dengue IgG (p = 0.042) — suggesting ongoing antibody-driven IC formation
  • FcγRIIa-HH genotype association with persistent symptoms
  • Critical methodological note: ANA tested on rat liver tissue, not HEp-2 — rat liver is less sensitive, so 23.1% is a floor estimate
  • No healthy control group tested for ANA — a major limitation
  • The autoimmune marker subset is only n=26 — hypothesis-generating, not definitive
  • Read this paper asking: is this true autoimmunity, or post-infectious inflammation that mimics autoimmune markers?

14. raw/Sungnak2025.pdf

Sungnak2025 - Distinct Immune Responses Asymptomatic Symptomatic Dengue | Sci Transl Med | Single-cell transcriptomics

Emphasis areas:

  • The autoantibody panel result: 120 autoantibody targets tested, no significant differences across asymptomatic/DF/DHF — this is a negative finding that constrains the autoimmunity narrative
  • CD8 T cell phenotype: effector memory in asymptomatic vs. exhausted in symptomatic — not directly ANA-related but important for understanding protective vs. pathological immune responses
  • NK cell FcεRIγ-negative phenotype in asymptomatic donors — adaptive NK cells
  • IGHG1/IGHA1 plasmablast enrichment in DHF — relevant to antibody-mediated pathology
  • Public BCR clonotype shared across donors — potential therapeutic target
  • The DENV-2 absence limitation — relevant for generalisability

Layer 6 — The Dengue-ANA Intersection

The payoff. Read these last — they make full sense only with all preceding layers as context.

15. raw/Chatterjee2024.pdf

Chatterjee2024 - ANA Detection in Dengue Kolkata | Virulence | ANA in acute dengue

Emphasis areas:

  • 54.8% ANA-IIFA positive (HEp-2) in acute dengue vs. 10.3% controls — the highest dengue-ANA figure in the wiki
  • But only 18.5% LIA-positive — the ~3:1 IIFA:LIA ratio means most dengue ANAs are non-specific (no defined autoantibody target)
  • Only MCTD and myositis significantly elevated on multivariate analysis — but wide confidence intervals (OR 14-18, CIs spanning 2-122)
  • DFS70 used as exclusion marker for systemic rheumatic disease — methodologically important
  • Compare the 54.8% acute-phase figure against Berlin2007’s 21.7% — dengue produces substantially more ANA than generic viral infections, even at the acute phase
  • Compare against Garcia2009’s 23.1% at 2 years — does this suggest ANA peaks acutely then partly resolves but remains elevated?
  • Arthralgia and body ache associated with ANA-IIFA positivity — clinical phenotype of dengue-associated ANA

16. raw/Shih2023.pdf

Shih2023 - Autoimmune Disease Risk After Dengue | PLoS Negl Trop Dis | The reality check

Emphasis areas:

  • 63,814 lab-confirmed dengue patients vs. 255,256 matched controls — by far the largest study in the wiki
  • Only ADEM (acute disseminated encephalomyelitis) significantly elevated (aHR 2.72) after Bonferroni correction — and only in the first month
  • All chronic autoimmune diseases (SLE, RA, Sjogren’s, GBS, etc.) — not significantly elevated
  • The Li et al. 2018 critique: 51.4% misclassification rate in prior “dengue” cohort studies — methodological warning for the whole field
  • The central tension to sit with: Garcia2009 shows autoimmune markers at 2 years, Chatterjee2024 shows 54.8% ANA acutely, Lin2006/2011 demonstrate molecular mimicry mechanism — yet Shih2023 shows no lasting autoimmune disease at population level. Reconciliation: autoimmune activation is real but subclinical and transient in the vast majority; only ADEM (itself a transient condition) reaches clinical significance
  • This paper should be your anchor for calibrating all other findings — it prevents over-interpreting mechanistic and small-cohort data

After Reading — Discussion Threads

With all 16 papers read, the key questions for our discussion on ANA and dengue dynamics are:

  1. Transience vs. persistence: Berlin2007 shows infection-triggered ANA resolves in weeks. Garcia2009 shows it at 2 years. Chatterjee2024 shows 54.8% acutely. What is the actual kinetic curve of dengue-associated ANA?

  2. Specificity vs. epiphenomenon: Are dengue-associated ANAs functionally pathogenic (like the anti-NS1 autoantibodies in Lin2006) or non-specific polyclonal noise? The 3:1 IIFA:LIA ratio in Chatterjee2024 suggests mostly the latter — but the MCTD/myositis signal complicates this.

  3. The Shih2023 paradox: How do we reconcile robust mechanistic evidence for dengue autoimmunity with population-level evidence showing almost no clinical autoimmune disease? Is there a “subclinical autoimmune activation” category that dengue occupies?

  4. FcγRIIa as the gate: Garcia2009/2010 implicate HH genotype in persistent autoimmune markers. Is FcγRIIa the genetic switch that determines whether transient dengue-triggered ANA becomes persistent?

  5. Dengue-specific vs. generic viral ANA: Berlin2007 gives 21.7% for generic viral infections. Chatterjee2024 gives 54.8% for dengue specifically. Is the difference real, and if so, does NS1 molecular mimicry explain it?

Graph View

Backlinks